Previous Close | 12.58 |
Open | 12.61 |
Bid | 12.57 x 0 |
Ask | 12.71 x 0 |
Day's Range | 12.58 - 12.61 |
52 Week Range | 9.27 - 15.43 |
Volume | |
Avg. Volume | 270 |
Market Cap | 340.917M |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.82 |
Earnings Date | May 09, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.